From: CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer
Drug | CRISPR/Cas9-targeted gene | Type of cancer cell | Total effect | References |
---|---|---|---|---|
Doxorubicin | ABCB1 | Epidermoid carcinoma and colorectal cancer | Accumulation of drug in the cancer cells and increasing chemosensitivity | [81] |
Doxorubicin | MDR1 | Breast cancer | Accumulation and uptake of drug in the cells and increasing the cytotoxicity of drug | [82] |
Doxorubicin | ABCB1 | Ovarian cancer | Increasing chemosensitivity | [83] |
Doxorubicin | ABCB1 | Osteosarcoma | Decreasing doxorubicin resistance | [84] |
Cisplatin and oxaliplatin | GSTO1 | Colorectal cancer | Increasing the cytotoxicity of drugs | [85] |
Palbociclib | CDK6 | Breast cancer | Increasing cancer cell sensitivity to anticancer drug and reducing cancer cell survival | [89] |
Doxorubicin, gemcitabine, and docetaxel | PARP1 | Triple-negative breast cancer | Increasing chemosensitivity and the inhibition of cancer cell growth | |
Temozolomide | RECQL4 | Glioma | Increasing DNA damage and apoptotic markers | [98] |
Cetuximab | KRAS | Colorectal cancer | Increasing apoptosis induction and reducing tumor size | [106] |
Doxorubicin | TP53 | Osteosarcoma | Reducing anti-apoptotic proteins | [110] |
Sunitinib | EGFR | Renal cancer | Reducing cancer cell proliferation | [115] |
5-FU, cisplatin, docetaxel, and doxorubicin | uPAR | HCT8/T and KBV200 | Reducing IC50 and attenuating drug resistance | [119] |
Gemcitabine | MUC4 | Pancreatic cancer | Increasing chemosensitivity | [122] |
Etoposide | TOP2α/90↓ TOP2α/170↑ | Etoposide-resistant leukemia cells | Increasing chemosensitivity | [125] |
Imatinib | BCR/ABL | Chronic myeloid leukemia | Reducing cell proliferation and increasing apoptosis in resistant cells | [126] |
Cisplatin | RUNX1 | Ovarian cancer | Increasing chemosensitivity | [128] |
Colchicine and paclitaxel | PI3K-110α and PI3K-110β (Pik3ca and Pik3cb) | Epidermoid carcinoma and lung cancer | Increasing chemosensitivity | [131] |
Cisplatin, vinorelbine, and carboplatin | NFE2L2 | Lung cancer | Increasing chemosensitivity | [134] |
Doxorubicin and paclitaxel | PDL-1 | Osteosarcoma | Reducing IC50 and increasing chemosensitivity | [133] |
Docetaxel | NANOG1 and NANOGP8 | Prostate cancer | Increasing chemosensitivity | [135] |
Doxorubicin | CD44 | Osteosarcoma | Reducing ABCB1 expression and increasing chemosensitivity | [140] |
Sorafenib and 5-FU | CD44 | Hepatocellular carcinoma | increasing chemosensitivity | [141] |
Cisplatin | miR-371/372/373/373 cluster | Oral carcinoma | Induction of apoptotic effect of drug and increasing chemosensitivity | [143] |
Paclitaxel | miR-21 | Ovarian cancer | Increasing chemosensitivity Attenuating EMT | [144] |
Doxorubicin and paclitaxel | lncRNA MALAT1 | Triple-negative breast cancer | Increasing chemosensitivity | [145] |
Cisplatin | HPV16 E6/E7 | Cervical cancer cells and xenograft mouse models | Inducing apoptosis and inhibiting cell growth as well as reducing cell proliferation |